[go: up one dir, main page]

ATE469648T1 - Zusammensetzungen und deren verwendung zur behandlung von krebs - Google Patents

Zusammensetzungen und deren verwendung zur behandlung von krebs

Info

Publication number
ATE469648T1
ATE469648T1 AT02797864T AT02797864T ATE469648T1 AT E469648 T1 ATE469648 T1 AT E469648T1 AT 02797864 T AT02797864 T AT 02797864T AT 02797864 T AT02797864 T AT 02797864T AT E469648 T1 ATE469648 T1 AT E469648T1
Authority
AT
Austria
Prior art keywords
compositions
cancer
treatment
treating cancer
tumorigenesis
Prior art date
Application number
AT02797864T
Other languages
English (en)
Inventor
Cynthia Bamdad
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Application granted granted Critical
Publication of ATE469648T1 publication Critical patent/ATE469648T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02797864T 2001-09-05 2002-09-05 Zusammensetzungen und deren verwendung zur behandlung von krebs ATE469648T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31730201P 2001-09-05 2001-09-05
US37673202P 2002-05-01 2002-05-01
PCT/US2002/028576 WO2003020279A2 (en) 2001-09-05 2002-09-05 Compositions and methods of treatment of cancer

Publications (1)

Publication Number Publication Date
ATE469648T1 true ATE469648T1 (de) 2010-06-15

Family

ID=26980879

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02797864T ATE469648T1 (de) 2001-09-05 2002-09-05 Zusammensetzungen und deren verwendung zur behandlung von krebs

Country Status (7)

Country Link
US (4) US8349853B2 (de)
EP (4) EP1425016B1 (de)
JP (1) JP2005507876A (de)
AT (1) ATE469648T1 (de)
CA (1) CA2459583A1 (de)
DE (1) DE60236605D1 (de)
WO (1) WO2003020279A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
JP4564714B2 (ja) 2000-11-27 2010-10-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
ATE469648T1 (de) 2001-09-05 2010-06-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
CA2475879A1 (en) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
US20080070864A1 (en) * 2002-03-07 2008-03-20 X-Ceptor Therapeutics, Inc. Quinazolinone Modulators Of Nuclear Receptors
NZ537076A (en) * 2002-05-09 2007-06-29 Cytokinetics Inc Pyrimidinone compounds, compositions and methods
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003236527A1 (en) * 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004009036A2 (en) 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
WO2004018058A2 (en) * 2002-08-21 2004-03-04 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003277079A1 (en) 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
JP2007531505A (ja) * 2002-11-27 2007-11-08 ミネルバ バイオオテクノロジーズ コーポレーション 癌（ｍｕｃ１）の診断および治療のための技術および組成物
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
JP2007510652A (ja) * 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−４−オン化合物、組成物、および方法
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
WO2005061460A1 (en) * 2003-12-08 2005-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
DK1737461T3 (da) 2004-03-15 2013-03-18 Ptc Therapeutics Inc Carbolin-derivater til inhibering af angiogenese
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US20080064680A1 (en) * 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
US11202775B2 (en) 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
EP2214485B1 (de) * 2007-09-25 2016-07-20 Minerva Biotechnologies Corp. Verfahren für die behandlung von krebs
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
JP2012504961A (ja) 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Ｍｕｃ１＊抗体
US8697662B2 (en) 2009-05-27 2014-04-15 Ptc Therapeutics, Inc. Methods for treating Kaposi sarcoma
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
MX394033B (es) 2009-05-27 2025-03-24 Ptc Therapeutics Inc Un Método para Inhibir o Reducir una Infección Viral por Coronavirus
JP2012532144A (ja) * 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
CN103998598A (zh) 2011-10-17 2014-08-20 米纳瓦生物技术公司 用于干细胞增殖和诱导的培养基
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6546087B2 (ja) * 2012-07-24 2019-07-17 ミネルバ バイオテクノロジーズ コーポレーション Ｎｍｅバリアント種の発現および抑制
JP6664219B2 (ja) 2012-08-14 2020-03-13 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞増強治療法
AU2014218872A1 (en) * 2013-02-20 2015-10-08 Minerva Biotechnologies Corporation NME inhibitors and methods of using NME inhibitors
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3119397T (pt) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20200035292A (ko) 2017-08-01 2020-04-02 피티씨 테라퓨틱스, 인크. 혈액 암 치료에 사용하기 위한 dhodh 억제제
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US46997A (en) * 1865-03-28 James m
DE2027645A1 (de) 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
AT335462B (de) * 1972-10-28 1977-03-10 Yamanouchi Pharma Co Ltd Verfahren zur herstellung neuer 1-nitrosoharnstoffderivate
CA2037669A1 (en) * 1990-03-12 1991-09-13 Noriki Ito Urea derivatives and salts thereof, pharmaceutical compositions containing the same, and methods for producing the same
GB9205907D0 (en) * 1992-03-18 1992-04-29 Cancer Res Inst Royal Anti-cancer compounds
US5464866A (en) * 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
JPH07258224A (ja) 1994-03-24 1995-10-09 Dai Ichi Seiyaku Co Ltd 二環性化合物
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
EP1137938A4 (de) 1998-12-08 2003-03-19 Smithkline Beecham Corp Verfahren zum screenen von agonisten und antagonisten des hdpxu17-rezeptors
AU3347900A (en) 1999-01-23 2000-08-07 Minerva Biotechnologies Corporation Interaction of colloid-immobilized species with species on non-colloidal structures
EP1169646A2 (de) 1999-01-25 2002-01-09 Minerva Biotechnologies Corporation Schneller und empfindlicher nachweis fehlerhafter proteinaggregation bei neurodegenerativen erkrankungen
WO2000077031A2 (en) * 1999-06-15 2000-12-21 University Health Network Muc1 ligands
US6559160B1 (en) 1999-08-27 2003-05-06 Chemocentryx, Inc. Compounds and methods for modulating cxcr3 function
US6319915B1 (en) * 1999-08-27 2001-11-20 Pfizer Inc. Benzazepine derivatives as inhibitors of hyperproliferation diseases
EP1216234B1 (de) 1999-09-16 2004-12-29 Curis, Inc. Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
EP1226129B1 (de) * 1999-10-27 2006-05-24 Cytokinetics, Inc. Chinazolinone benutzende verfahren und zusammenstellungen
US6683108B1 (en) * 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
EP1328261A2 (de) 2000-04-12 2003-07-23 Minerva Biotechnologies Corporation Behandlung von neurodegenerativen krankheiten
JP4564714B2 (ja) 2000-11-27 2010-10-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
ES2248412T3 (es) * 2001-02-12 2006-03-16 Lilly Icos Llc Derivados de carbolina.
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
ATE469648T1 (de) 2001-09-05 2010-06-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
WO2003020280A2 (en) * 2001-09-05 2003-03-13 Minerva Biotechnologies Corporation Compositions and use thereof in the treatment of cancer

Also Published As

Publication number Publication date
US20170246168A1 (en) 2017-08-31
EP2116248A1 (de) 2009-11-11
US8349853B2 (en) 2013-01-08
US9649312B2 (en) 2017-05-16
EP1425016A2 (de) 2004-06-09
DE60236605D1 (de) 2010-07-15
WO2003020279A3 (en) 2003-10-23
EP2340838A1 (de) 2011-07-06
US20130190495A1 (en) 2013-07-25
US20030130293A1 (en) 2003-07-10
WO2003020279A2 (en) 2003-03-13
US20160324858A1 (en) 2016-11-10
JP2005507876A (ja) 2005-03-24
EP1425016B1 (de) 2010-06-02
EP2329822A1 (de) 2011-06-08
CA2459583A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
ATE469648T1 (de) Zusammensetzungen und deren verwendung zur behandlung von krebs
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE602006010991D1 (de) 3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs
ATE438411T1 (de) Dosierung für die behandlung mit anti erbb2- antikörpern
DE602006017965D1 (de) Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
ATE429442T1 (de) Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie
CY1110742T1 (el) Αναστολεις ινδαζολης, βενζισοξαζολης, και βενζισοθειαζολης
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
GB0207533D0 (en) Protein
DE69725825D1 (de) 5-HT1F-Agonisten
DE602007010447D1 (de) Verwendung von 4,17-beta-dihydroxyandrost-4-en-3-on zur behandlung von krebs
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE455763T1 (de) Piperidine und verwandte verbindungen zur behandlung von alzheimer-krankheit
WO2003061559A3 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
DE69902154D1 (de) Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung.
ATE339968T1 (de) Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
DE602006015373D1 (de) Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten
ID25478A (id) Agonis 5-ht1f
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
ATE347536T1 (de) Chlorsilanblends zur behandlung von quarzfuellstoffen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties